Fulcrum Therapeutics (FULC) vs Rocket Pharmaceuticals (RCKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rocket Pharmaceuticals (RCKT) has outperformed Fulcrum Therapeutics (FULC) over the past year, losing 30.2% versus a loss of 61.1%. Over five years, FULC leads with a -85.6% price change compared with -90.8% for RCKT. Fulcrum Therapeutics is the larger company by market cap ($287.6 million vs $281.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FULC | RCKT |
|---|---|---|
| Share price | $3.77 | $2.56 |
| Market cap | $287.64M | $281.02M |
| 1-day change | +0.53% | -2.66% |
| YTD return | -66.84% | -27.07% |
| 1-year return | -61.06% | -30.25% |
| 5-year return | -85.58% | -90.83% |
| EPS (TTM) | $-1.21 | $-0.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.74 | $5.45 |
| 52-week low | $2.83 | $2.42 |
| Distance from 52-week high | -76.05% | -53.03% |
| Analyst consensus | none | buy |
| Avg. price target upside | -2.65% | +232.03% |
| Average volume | 1.54M | 1.67M |
| Shares outstanding | 76.30M | 109.77M |
| Employees | 9 | 202 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RCKT has outperformed FULC by 30.8 percentage points over the past year.
About Fulcrum Therapeutics
FULC stock →Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Rocket Pharmaceuticals
RCKT stock →Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees
FULC vs RCKT FAQ
Which is bigger, Fulcrum Therapeutics or Rocket Pharmaceuticals?
Fulcrum Therapeutics (FULC) is larger, with a market capitalization of $287.64M compared with $281.02M for Rocket Pharmaceuticals (RCKT).
Which stock has performed better over the past year, FULC or RCKT?
RCKT returned -30.25% over the past 12 months, compared with -61.06% for FULC (price return, excluding dividends). Past performance does not predict future results.
Are Fulcrum Therapeutics and Rocket Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.